医学
乌斯特基努马
银屑病
依那西普
持久性(不连续性)
观察研究
荟萃分析
阿达木单抗
生物制剂
置信区间
内科学
皮肤病科
疾病
肿瘤坏死因子α
工程类
岩土工程
作者
Eugenia Piragine,Davide Petri,Alma Martelli,Agata Janowska,Valentina Dini,Marco Romanelli,Vincenzo Calderone,Ersilia Lucenteforte
摘要
Despite the large number of biologics currently available for moderate-to-severe psoriasis, poor adherence and persistence to therapy represent the main issues for both the clinical and economic management of psoriasis. However, the data about adherence and persistence to biologics in psoriasis patients are conflicting. Our aim was to produce summary estimates of adherence and persistence to biologics in adult patients with psoriasis. We performed a systematic review and meta-analysis of observational studies, searching two databases (PubMed and Embase). Sixty-two records met the inclusion criteria, and a meta-analysis was conducted on fifty-five studies. Overall, the proportion of adherent and persistent patients to biological therapy was 0.61 (95% confidence interval: 0.48-0.73) and 0.63 (0.57-0.68), respectively. The highest proportions were found for ustekinumab, while the lowest ones were found for etanercept. The proportions of adherence and persistence to biological drugs in psoriasis patients are sub-optimal. Notably, both proportions largely differ between drugs, suggesting that a more rational use of biologics might ensure better management of psoriasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI